FORA Capital’s United Therapeutics UTHR Stock Holding History

FORA Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,462	Closed	-$1.28M	–	679
2025 Q2	$1.28M	Sell	4,462 -5,227	-54%	-$1.56M	0.14%	182
2025 Q1	$2.99M	Buy	9,689 +4,318	+80%	+$1.48M	0.3%	110
2024 Q4	$1.9M	Buy	+5,371	New	+$1.97M	0.22%	137
2023 Q4	–	Sell	-5,603	Closed	-$1.27M	–	656
2023 Q3	$1.27M	Buy	+5,603	New	+$1.29M	0.11%	215
2023 Q1	–	Sell	-5,219	Closed	-$1.45M	–	710
2022 Q4	$1.45M	Buy	+5,219	New	+$1.32M	0.23%	116
2022 Q3	–	Sell	-5,162	Closed	-$1.22M	–	585
2022 Q2	$1.22M	Buy	+5,162	New	+$1.05M	0.24%	133
2021 Q3	–	Sell	-172	Closed	-$31K	–	858
2021 Q2	$31K	Buy	+172	New	+$32.8K	0.01%	779
2020 Q3	–	Sell	-902	Closed	-$109K	–	1002
2020 Q2	$109K	Sell	902 -6,636	-88%	-$747K	0.04%	469
2020 Q1	$715K	Buy	7,538 +3,106	+70%	+$295K	0.15%	169
2019 Q4	$390K	Buy	+4,432	New	+$390K	0.04%	458

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

FORA Capital's UTHR Position: Q3 2025 in Review

FORA Capital sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 4,462 shares — an estimated $1.28M sold.

FORA Capital first reported a position in UTHR in Q4 2019 and held it in 10 quarters. The position peaked at $2.99M in Q1 2025. 708 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

FORA Capital reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
FORA Capital sold 4,462 United Therapeutics shares in Q3 2025, an estimated $1.28M.
FORA Capital first reported a position in United Therapeutics in Q4 2019 and held it in 10 quarters.
FORA Capital's United Therapeutics position peaked at $2.99M in Q1 2025.
708 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on FORA Capital's 13F filing for Q3 2025, filed 13 Nov 2025.